Your email has been successfully added to our mailing list.

×
0 0 -0.00191728293618188 -0.00136948781155859 -0.000821692686935117 0.00489454943850997 0.00534100246507787 -0.000136948781155918
Stock impact report

GSK-J&J's long-acting HIV injection gets EU panel endorsement [Reuters]

GlaxoSmithKline Plc (GSK)  More Company Research Source: Reuters
US:NYSE Investor Relations: gsk.com/en-gb/investors
PDF GSK-J&J's long-acting HIV injection gets EU panel endorsement By Reuters Staff 2 Min Read (Reuters) - GlaxoSmithKline Plc said an injection of its cabotegravir drug given every two months, in combination with Johnson & Johnson’s rilpivirine, was recommended for approval to treat HIV infections by a panel of the European health regulator. The treatment is a long-acting regimen, which can reduce the number of doses required to 12 or six per year instead of a daily intake of pills. If approved, it would be the first complete long-acting HIV regimen requiring dosing just once in two months (in the EU region), GSK said. The combination as an injection is already approved in Canada and is currently under review in the United States. Shares of GSK were trading up 2.5% at 1410.4p, while J&J shares were marginally up during premarket trading. Gilead’s Truvada daily oral pill is currently the standard of care for preventing HIV, but GSK hopes to challenge its dominance by making shorter, long- [Read more]
Impact snapshot Event time: GSK
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
GSK alerts
from News Quantified
Opt-in for
GSK alerts

from News Quantified
Opt-in for
GSK alerts

from News Quantified